Immuno modulator-1 (compound 22) effectively suppresses the secretion of TNFα and IL-2 in human peripheral blood mononuclear cells (hPBMC) with IC50 values of 4.7 nM and 26 nM, respectively. Additionally, this compound exhibits a 20% inhibitory effect on the hERG potassium channel at a concentration of 3 μM [1].

免疫调节剂-1（化合物22）通过降低NCI-H929人骨髓瘤细胞的增殖作用，展现出抑制活性，其半抑制浓度(IC50)为0.6 nM [1]。

Immuno modulator-1（化合物22）在雄性Sprague-Dawley大鼠中以1 mg/kg（静脉注射，IV）和5 mg/kg（口服，PO）剂量单次给药后，展现了30%的口服生物利用度[1]。